These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11442896)

  • 21. Vitamin D Deficiency in Ambulant Children on Carbamazepine or Sodium Valproate Monotherapy.
    Sreedharan M; Devadathan K; Mohammed Kunju PA; Sasidharan B; Pillai JP; Vasumathy Amma MA; Muthubeevi S
    Indian Pediatr; 2018 Apr; 55(4):307-310. PubMed ID: 29428922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of sex hormones and sperm parameters in male epileptic patients.
    Ocek L; Tarhan H; Uludağ FI; Sarıteke A; Köse C; Colak A; Zorlu F; Zorlu Y
    Acta Neurol Scand; 2018 Apr; 137(4):409-416. PubMed ID: 29315457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproic-acid-induced thrombocytopenia and hepatotoxicity: discontinuation of treatment?
    Lackmann GM
    Pharmacology; 2004 Feb; 70(2):57-8. PubMed ID: 14685007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine.
    Battino D; Croci D; Granata T; Bernardi G; Monza G
    Ther Drug Monit; 1992 Oct; 14(5):376-9. PubMed ID: 1448844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction.
    Kurahashi H; Takami A; Murotani K; Numoto S; Okumura A
    Int J Hematol; 2018 Jan; 107(1):105-111. PubMed ID: 28879549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients.
    McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
    Epilepsy Res; 1992 May; 11(3):193-8. PubMed ID: 1396534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment?
    Oz O; Gökçil Z; Bek S; Cakir E; Odabaşi Z
    Epilepsy Res; 2009 Nov; 87(1):54-8. PubMed ID: 19713077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy.
    Zhou D; Wang Y; Hopp P; Kerling F; Kirchner A; Pauli E; Stefan H
    Epilepsia; 2002 Apr; 43(4):386-93. PubMed ID: 11952768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy.
    Schoeman JF; Elyas AA; Brett EM; Lascelles PT
    Dev Med Child Neurol; 1984 Dec; 26(6):756-64. PubMed ID: 6440825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents.
    Rambeck B; Sälke-Treumann A; May T; Boenigk HE
    Eur Neurol; 1990; 30(2):79-83. PubMed ID: 2111243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid and thrombocytopenia in children: a case-controlled retrospective study.
    Allarakhia IN; Garofalo EA; Komarynski MA; Robertson PL
    Pediatr Neurol; 1996 May; 14(4):303-7. PubMed ID: 8805173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal dysfunctions/injury in adult epilepsy patients treated with carbamazepine or valproate.
    Hamed SA; Rageh TA; Mohamad AO; Abou Elnour SM
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):819-824. PubMed ID: 30009654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of carbamazepine and valproate in different dose proportions in maximal electroshock seizure model in mice.
    Sun Mz; van Rijn CM; Liu Yx; Wang Mz
    Epilepsy Res; 2002 Sep; 51(1-2):5-11. PubMed ID: 12350379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbamazepine-induced thrombocytopenia defined by a challenge test.
    Ishikita T; Ishiguro A; Fujisawa K; Tsukimoto I; Shimbo T
    Am J Hematol; 1999 Sep; 62(1):52-5. PubMed ID: 10467277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valproate treatment and platelet function: the role of arachidonate metabolites.
    Kis B; Szupera Z; Mezei Z; Gecse A; Telegdy G; Vécsei L
    Epilepsia; 1999 Mar; 40(3):307-10. PubMed ID: 10080510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Half pitch lower sound perception caused by carbamazepine.
    Konno S; Yamazaki E; Kudoh M; Abe T; Tohgi H
    Intern Med; 2003 Sep; 42(9):880-3. PubMed ID: 14518681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence of thrombocytopenia in psychiatric patients taking valproate.
    Trannel TJ; Ahmed I; Goebert D
    Am J Psychiatry; 2001 Jan; 158(1):128-30. PubMed ID: 11136646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.
    Corman CL; Leung NM; Guberman AH
    Can J Neurol Sci; 1997 Aug; 24(3):240-4. PubMed ID: 9276111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ursodeoxycholate improves hepatobiliary dysfunction induced by valproate-carbamazepine treatment in the rat.
    Mesdjian E; Zamora AJ; Montet AM; Bonneton J; Guitaoui M; Genton P; Montet JC
    Life Sci; 1996; 59(13):1069-79. PubMed ID: 8809226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Levels of Valproic Acid and Carbamazepine Do Not Correlate Well with End-Organ Dysfunction.
    Myers KA; Tamon U; Agnihotram RV; Berrahmoune S
    Epilepsy Res; 2020 Jul; 163():106343. PubMed ID: 32339984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.